GW Pharma and Almirall have completed European Mutual Recognition Procedure (MRP) for Sativex in the treatment of spasticity due to Multiple Sclerosis (MS).
The companies have already received approval for this MS drug in the UK and Spain.
With the completion of MRP, now the companies are anticipating to get approvals in Germany, Italy, Denmark, Sweden, Austria and the Czech Republic.
Almirall chief scientific officer Bertil Lindmark said Sativex is the first drug which provides MS patients with a treatment option to mitigate spasticity and other related symptoms.